

Supplementary Table 1. Interventions and schedule of administration in group A and B

	Group A			Group B		
	06:00	12:00	18:00	06:00	12:00	18:00
Omeprazole (mg)	20		20	20		placebo
Tetracycline (mg)	750	750	750	placebo	placebo	placebo
Metronidazole (mg)	400	400	400	placebo	placebo	placebo
Bismuth citrate (mg)	300		300	300		placebo

Supplementary Table 2. Prevalence of *H. pylori* infection stratified by sex, age and township ^a

Characteristics	No. of participants	<i>H. pylori</i> positive	<i>P</i> ^b
Total	183970	105973 (57.6)	
Sex			< 0.0001
Men	84353	49765 (59.0)	
Women	99617	56208 (56.4)	
Age, years			<0.0001
25-29	19438	11571 (59.5)	
30-34	14399	8578 (59.6)	
35-39	25882	15388 (59.5)	
40-44	38485	22650 (58.9)	
45-49	44081	25146 (57.0)	
50-54	41685	22640 (54.3)	
Township			<0.0001
Xinzhai	22361	13221 (59.1)	
Yishan	17724	10757 (60.7)	
Sitou	15352	8952 (58.3)	
Yeyuan	17044	9429 (55.3)	
Jiushan	12298	6732 (54.7)	
Wujing	15420	8902 (57.7)	
Dongcheng	27903	16465 (59.0)	
Chengguan	21670	13006 (60.0)	
Longgang	19342	10530 (54.4)	
Liushan	13502	7231 (53.6)	
Other	1354	748 (55.2)	

^a Data are presented as n or n (%)

^b *P* value was calculated by Chi-Square Test

Supplementary Table 3. Side-effects in the different treatment groups ^a

Side-effects	Group A (n=44345)	Group B (n=43930)	<i>P</i> ^b
Rash	193 (0.43)	118 (0.27)	< 0.0001
Itch skin	22 (0.05)	13 (0.03)	0.1352
Edema	21 (0.05)	11 (0.03)	0.0816
Nausea and vomiting	567 (1.28)	217 (0.49)	< 0.0001
Abdominal pain	47 (0.11)	25 (0.06)	0.0107
Distention and diarrhea	24 (0.05)	20 (0.05)	0.5673
Headache	24 (0.04)	14 (0.03)	0.1110
Dizziness	18 (2.07)	12 (0.03)	0.2847
Total	916 (2.3)	430 (0.98)	< 0.0001

^a Data are presented as n (%)

^b *P* value was calculated by Chi-Square Test